Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.58 |
| ▸ | EPHA2 | P29317 | 13/20 | 0.49 |
| ▸ | KDR | P35968 | 11/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 11/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354598 | 0.84 | EPHA2 (0.47) | ENPP1EPHA2KDREPHB4NPC1 | |
| SCHEMBL22441582 | 0.84 | EPHA2 (0.47) | ENPP1EPHA2KDREPHB4NPC1 | |
| SCHEMBL5177457 | 0.79 | KDM4E (0.54) | EPHA2KDREPHB4NPC1RAB9A | |
| SCHEMBL16760347 | 0.78 | EPHA2 (0.67) | ENPP1EPHA2KDREPHB4ERBB2 | |
| SCHEMBL5177474 | 0.78 | TRPA1 (0.43) | EPHA2KDREPHB4ERBB2KDM1A | |
| SCHEMBL1013021 | 0.77 | ENPP1 (0.79) | ENPP1EPHA2KDREPHB4 | |
| SCHEMBL1011724 | 0.77 | ENPP1 (0.79) | ENPP1KDRKDM1A | |
| SCHEMBL662795 | 0.77 | ENPP1 (0.79) | ENPP1EPHA2KDREPHB4 | |
| SCHEMBL30053845 | 0.77 | ENPP1 (0.79) | ENPP1KDRKDM1A | |
| SCHEMBL1010156 | 0.77 | ENPP1 (0.79) | ENPP1KDRKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-8153643-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | disclosed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| EP-1802591-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040520-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | ENPP1 3166/4885EPHA2 3540/4885KDR 29/4885 |
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | ENPP1 3031/4885EPHA2 3814/4885KDR 27/4885 |
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | AQP1, F12, AQP3 | ENPP1 3092/4885EPHA2 3912/4885KDR 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.